The sub-optimal tumor control against NALM6 in vivo reflects that, despite the optimization steps, maximal TetCAR activity to lower CD19 surface density targets showed significantly reduced cytokine secretion and proliferation compared to the monolithic CAR. Here, CD19 is linked to neoplasm.